Penumbra, Inc. revealed that data from wearable fitness devices in the STORM-PE trial showed a strong correlation between daily step activity and clinical recovery in patients with intermediate-high risk pulmonary embolism (PE) treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation versus anticoagulation alone. Patients using CAVT showed better right ventricular recovery and functional improvement, confirmed by both clinical 6-minute walk tests and real-world step tracking. This is the first trial to integrate consumer wearable data to assess real-world recovery, offering new insights for future PE treatment and clinical trial designs. Complementary results from the STRIKE-PE trial further support the safety and long-term benefits of CAVT in improving patient quality of life.
New data from the STORM-PE trial on wearable technology in pulmonary embolism patients provide a context for health-sector market activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 06, 2026 19:45 WIB: Of 100 priced US health stocks, 67 rose and 24 fell. Notable movers include AMLX at USD 28.49 with a 2.56% increase and 100% buy order activity, SYK at USD 278.00 with a 2.53% decrease and 98% sell order activity, and AZN at USD 160.35 with a 2.44% increase and 95% buy order activity.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
